Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28562729 | 0.97 | CA2 (0.50) | CA2CYP2A6ALDH1A1CA12CA3 | |
| Water SCHEMBL28189314 | 0.83 | CA2 (0.69) | CA2CYP2A6ALDH1A1CA12CA3 | |
| Water SCHEMBL28254092 | 0.83 | CA2 (0.69) | CA2CYP2A6ALDH1A1CA12CA3 | |
| SCHEMBL2503454 | 0.83 | CA2 (0.69) | CA2CYP2A6ALDH1A1CA12CA3 | |
| SCHEMBL45942 | 0.83 | CA2 (0.69) | CA2CYP2A6ALDH1A1CA12CA3 | |
| Fluoride SCHEMBL28136789 | 0.79 | CA2 (0.65) | CA2CYP2A6ALDH1A1CA12CA3 | |
| SCHEMBL27486388 | 0.79 | CA2 (0.65) | CA2CYP2A6ALDH1A1CA12CA3 | |
| SCHEMBL28829194 | 0.79 | CA2 (0.65) | CA2CYP2A6ALDH1A1CA12CA3 | |
| SCHEMBL27949151 | 0.79 | CA2 (0.65) | CA2CYP2A6ALDH1A1CA12CA3 | |
| SCHEMBL27567478 | 0.79 | CA2 (0.65) | CA2CYP2A6ALDH1A1CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113200905-A | Chiral indolone derivative and synthesis method thereof | 中山大学 | 2021-08-03 | — | — | CN | claimed |
| US-8231941-B2 | Procedure for preparing redox-active polymers on surfaces | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-31 | — | — | US | claimed |
| US-20100330284-A1 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-30 | — | — | US | claimed |
| US-7452572-B1 | Procedure for preparing redox-active polymers on surfaces | THE NORTH CAROLINA STATE UNIVERSITY (US) | 2008-11-18 | — | — | US | claimed |
| US-20080280047-A1 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-11-13 | — | — | US | claimed |
| CN-101248066-A | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-08-20 | — | — | CN | claimed |
| CN-101248056-A | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-08-20 | — | — | CN | claimed |
| EP-1902049-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-7312100-B2 | In situ patterning of electrolyte for molecular information storage devices | THE NORTH CAROLINA STATE UNIVERSITY (US) | 2007-12-25 | — | — | US | claimed |
| EP-1809473-A2 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006136461-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20050207208-A1 | Situ patterning of electrolyte for molecular information storage devices | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-09-22 | — | — | US | claimed |
| WO-2005086826-A2 | PROCEDURE FOR PREPARING REDOX-ACTIVE POLYMERS ON SURFACES | THE REGENTS OF THE UNIVERSITY (US) | 2005-09-22 | — | — | WO | claimed |
| US-6944047-B2 | Variable-persistence molecular memory devices and methods of operation thereof | NORTH CAROLINA STATE UNIVERSITY (US) | 2005-09-13 | — | — | US | claimed |
| WO-2005017953-A2 | IN SITU PATTERNING OF ELECTROLYTE FOR MOLECULAR INFORMATION STORAGE DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-24 | — | — | WO | claimed |
| CN-1582287-A | Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | CN | claimed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | claimed |
| US-20040120180-A1 | Variable-persistence molecular memory devices and methods of operation thereof | NORTH CAROLINA STATE UNIVERSITY | 2004-06-24 | — | — | US | claimed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | CA2 561/4885CYP2A6 1458/4885ALDH1A1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.